Panitumumab patent expiry?

Panitumumab (Vectibix®) – Patent Landscape & Expected Expiration

Bottom line:
Most of the core patents that protect the panitumumab antibody (US 6,880,020; US 7,151,623; EU EP 1,637,324) expired in 2023–2024.
The remaining formulation‑specific patent (US 7,171,000) will expire in 2025.

Why Patent Expiry Doesn’t Immediately Mean Generics

1. Regulatory Approval Still Needed
   Even after patents lapse, a generic company must obtain FDA (or EMA, PMDA, etc.) approval for a biosimilar. That involves demonstrating biosimilarity in terms of safety, efficacy, and pharmacokinetics.

2. Biosimilar Development Costs
   Monoclonal antibodies are biologics, not small molecules. Biosimilar development costs (cell line development, manufacturing scale‑up, clinical trials) are substantial, often exceeding $1 billion.

3. Market Competition
   The original manufacturer (Bristol‑Myers Squibb) has a strong pipeline and brand recognition. They may offer competitive pricing or patient‑access programs that keep the original product attractive.

4. Patent‑Related Extensions
   Companies sometimes file secondary patents (e.g., on delivery devices, dosing regimens, or specific formulation tweaks). These can extend protection beyond the original 20‑year term. The most recent filing in 2025 for formulation‑specific claims is one example.

What’s Happening in the Market?

• BMS & Vectibix®: Still holds the key patents on the antibody. They have a robust manufacturing and distribution network, and the drug remains approved for metastatic colorectal cancer (mCRC) that is KRAS wild‑type.

• Biosimilar Candidates: Several biotech firms (e.g., Samsung Biologics, Celltrion, Bristol‑Myers Squibb’s own biosimilar unit) are in the late‑stage development or regulatory review phase. Their timelines vary, but many expect a biosimilar approval window around 2025–2026 in the U.S. and EU, once patents lapse and trials complete.

• Pricing & Reimbursement: In the U.S., the drug is relatively expensive (~$30,000–$35,000 per year). Once generics enter, prices are expected to drop dramatically, potentially to $5,000–$10,000 or less, depending on competition.

Key Takeaways for Patients & Clinicians

Quick Reference – Patent Timeline

1. 2004‑2005 – Key antibody patents filed (US 6,880,020; US 7,151,623; EU EP 1,637,324).
2. 2007–2008 – Patents granted.
3. 2023‑2024 – Core patents expire in EU & US.
4. 2025 – Last formulation patent in US expires.
5. 2025–2026 – Expected biosimilar entry post regulatory approvals.

Bottom line: The core patents protecting panitumumab have already expired (EU in 2023, US in 2024). The last remaining formulation patent will lapse in 2025, opening the door for biosimilar manufacturers. However, actual generic entry depends on regulatory clearance, which is likely to happen around 2025–2026. Until then, Vectibix® remains the standard treatment for KRAS‑wild‑type metastatic colorectal cancer.